Thyroid dysfunction in Hashimoto’s thyroiditis: a pilot study on the putative role of miR-29a and TGFβ1

Purpose: Hashimoto’s thyroiditis (HT) is one of the most common causes of thyroid dysfunction in iodine sufficient worldwide areas, but its molecular mechanisms are not completely understood.

To this regard, this study aimed to assess serum levels of miRNA-29a (miR-29a) and transforming growth factor beta 1 (TGFβ1) in HT patients with different patterns of thyroid function.

Methods: A total of 29 HT patients, with a median age of 52 years (21–68) were included.

Of these, 13 had normal thyroid function (Eu-HT); 8 had non-treated hypothyroidism (Hypo-HT); 8 had hypothyroidism on replacement therapy with LT4 (subst-HT).

All patients had serum miR-29a assayed through qRT-PCR and serum TGFβ1 assayed by ELISA.

Results: Serum miR-29a levels were significantly down-regulated in patients with Hypo-HT compared to Eu-HT patients (P < 0.01) and subst-HT patients (P < 0.05).

A significant negative correlation was detected between serum miR-29a levels and TSH levels (r = −0.60, P < 0.01).

Serum TGFβ1 levels were significantly higher in Hypo-HT than both Eu-HT (P < 0.01) and subst-HT patients (P < 0.05).

A negative correlation was observed between serum miR-29a and TGFβ1 (r = −0.75, P < 0.01).

Conclusions: In conclusion, Hypo-HT patients had lower levels of serum miR-29a and higher levels of TGFβ1 in comparison with Eu-HT patients.

Worthy of note, subst-HT patients showed restored serum miR-29a levels compared with Hypo-HT group, associated with lower serum TGFβ1.

These novel findings may suggest a possible impact of replacement therapy with levothyroxine on serum miR-29a levels in HT.